<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000223" GROUP_ID="AIRWAYS" ID="305299091412043978" MERGED_FROM="" MODIFIED="2008-09-02 12:30:20 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Doxapram in COPD&lt;br&gt;CJC check 3/10/99&lt;br&gt;References are not Vancouver style so the authors have all gone in the title field.  I have corrected the included studies but have not time to do all the excluded ones!&lt;br&gt;At some point I would recommend changing all the negative sign inputs into the outcomes and labelling each outcome to show the direction of the effect in Metaview.&lt;br&gt;This is not urgent and unlikely to have time to do this before the October deadline.&lt;br&gt;Please Make sure this version is used for further revisions!&lt;/p&gt;" NOTES_MODIFIED="2008-09-02 11:27:58 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="DOXA-COP" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-09-02 12:30:20 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2008-09-02 12:30:20 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="7552" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>Greenstone</LAST_NAME><POSITION>Consultant Chest Physician</POSITION><EMAIL_1>greenstone.mike@googlemail.com</EMAIL_1><EMAIL_2>mike.greenstone@hey.nhs.uk</EMAIL_2><ADDRESS><ORGANISATION>Castle Hill Hospital</ORGANISATION><CITY>Cottingham</CITY><ZIP>HU16 5JQ</ZIP><REGION>North Humberside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1482 875875</PHONE_1><FAX_1>+44 1482 876331</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-02 12:30:20 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="7552" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>Greenstone</LAST_NAME><POSITION>Consultant Chest Physician</POSITION><EMAIL_1>greenstone.mike@googlemail.com</EMAIL_1><EMAIL_2>mike.greenstone@hey.nhs.uk</EMAIL_2><ADDRESS><ORGANISATION>Castle Hill Hospital</ORGANISATION><CITY>Cottingham</CITY><ZIP>HU16 5JQ</ZIP><REGION>North Humberside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1482 875875</PHONE_1><FAX_1>+44 1482 876331</FAX_1></ADDRESS></PERSON><PERSON ID="8583" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Toby</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Lasserson</LAST_NAME><POSITION>Review Group Coordinator, CAG</POSITION><EMAIL_1>tlassers@sgul.ac.uk</EMAIL_1><URL>www.airways.cochrane.org</URL><ADDRESS><DEPARTMENT>Community Health Sciences</DEPARTMENT><ORGANISATION>St George's, University of London</ORGANISATION><ADDRESS_1>Cranmer Terrace</ADDRESS_1><ADDRESS_2>Tooting</ADDRESS_2><CITY>London</CITY><ZIP>SW17 ORE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+20 8725 2790</PHONE_1><FAX_1>+20 8725 3584</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-02 12:30:20 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 08/10/03&lt;/p&gt;&lt;p&gt;New studies sought but none found: 07/10/03&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 01/11/01&lt;/p&gt;&lt;p&gt;Conclusions changed: 05/08/02&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="7" MONTH="10" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="10" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="1997"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;This update review contains data from an additional unpublished study (Newman 2001). It compares doxapram with Non-invasive ventilation (NIV) in acute COPD. No numerical data have been entered into the analyses for continuous data due to non-parametric distribution. Data on mortality and treatment failure have been restricted to narrative description. &lt;br&gt;&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="2" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="5" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-02 11:27:58 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-09-02 11:15:37 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-09-02 11:15:37 +0100" MODIFIED_BY="Toby J Lasserson">Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>Some people with advanced COPD (chronic obstructive pulmonary disease) experience respiratory failure whereby blood oxygen levels fall and high levels of the waste gas carbon dioxide accumulate and cause worsening symptoms. In extreme cases this disturbance in the blood can cause coma and death. When respiratory failure is severe giving oxygen alone is no longer enough because an increase in carbon dioxide levels can make the situation worse by depressing the drive to breathe. Doxapram is a drug that may stimulate breathing. The review of trials found that it may be able to help, but some newer treatments may be more effective. Doxapram may be worthwhile as a short-term measure or when other treatments are not possible. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>COPD is a progressive illness and in the later stages, exacerbations may lead to ventilatory failure. The combination of hypoxia and hypercapnia can lead to coma and death. Correction of these blood gas abnormalities is a medical emergency. Doxapram is a respiratory stimulant used to stimulate respiration in this setting. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of doxapram on gas exchange and clinical outcomes in people with ventilatory failure due to acute exacerbations of chronic obstructive pulmonary disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Airways Group trials register and reference lists of articles. We also contacted experts in the field, study authors and drug companies. An updated electronic search conducted in October 2003 did not yield any further studies. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing doxapram with other treatments or placebo in people with ventilatory failure due to exacerbations of chronic obstructive pulmonary disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Four trials involving 176 people were included. The trials were of variable quality. Doxapram was marginally superior to placebo in preventing blood gas deterioration. In the two studies comparing doxapram and non-invasive ventilation the results were conflicting: an early small study suggested non-invasive ventilation was superior. However, a subsequent larger study in severe participants suggested doxapram was equally effective in terms of blood gases changes, with no differences observed in mortality and frequent treatment failure. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Doxapram can improve blood gas exchange over the first few hours of treatment. Newer techniques such as non-invasive ventilation may prove to be more effective, although there is no randomised trial evidence to this effect.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-02 11:27:58 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>Exacerbations of COPD are a common cause of admission to hospital and ventilatory failure as a result of this carries a high morbidity and significant mortality. Treatment of the blood gas abnormality is difficult because correction of hypoxia by administering oxygen can precipitate a further rise in CO2 levels and cause clinical deterioration. Current treatment includes inhaled bronchodilators, systemic corticosteroids, aminophylline, antibiotics and controlled oxygen administration. The ventilatory stimulant doxapram was introduced into clinical practice in the 1970s and is now part of the standard management of ventilatory failure associated with general anaesthesia and exacerbations of COPD. It works by stimulating both central and peripheral chemoreceptors to improve minute ventilation largely by increasing tidal volume. In subjects with ventilatory failure secondary to COPD, doxapram is used to allow correction of hypoxia without exacerbating the hypercapnia so that intubation and artificial ventilation may be avoided. The pharmacokinetics of doxapram are not very predictable, with the result that, in practice, the dosage is adjusted until an effect is produced.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether doxapram is effective in altering the disordered gas exchange and clinical outcome in patients with ventilatory failure secondary to acute exacerbations of COPD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-02 11:24:18 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-09-02 11:16:18 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Any randomised trial comparing blood gases in doxapram treated and non-doxapram treated groups of patients with ventilatory failure due to exacerbations of COPD.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with ventilatory failure (hypoxia and hypercapnia) due to an acute exacerbation of COPD. Only spontaneously breathing subjects were included. Those who had received general anaesthesia were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any intravenous injection or infusion of doxapram. Dose related changes were included in subgroups if available.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-09-02 11:16:18 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>Blood gas data</LI>
<LI>Clinical effects including progression to endotracheal intubation and artificial ventilation</LI>
<LI>Mortality and length of hospital stay</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-02 11:24:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We carried out an initial search using the Cochrane Airways Group COPD trials register using the search term:</P>
<P>doxapram* OR dopram*</P>
<P>This Procite-based register contains records downloaded from Medline, CINAHL and Embase, as well as records identified through hand searching and abstracts from meetings of the American Thoracic Society, British Thoracic Society and European Respiratory Society. Randomised controlled trials are identified in the Procite register using the following search strategy: (placebo* OR trial* OR random* OR double-blind OR double blind OR single-blind OR single blind OR controlled study OR comparative study).</P>
<P>Following this we searched the bibliographies of each RCT for additional papers that may contain RCTs. We contacted authors of identified RCTs for other published and unpublished studies. In addition, we contacted the pharmaceutical company that manufactures doxapram. Searches were up to date as of November 2003.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-02 11:24:13 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We assessed all trials that appeared potentially relevant , and if relevant they were included in the review. Data for the trial was extracted by two reviewers (MG and TL).</P>
<P>The methodological quality of the included trials was assessed with particular emphasis on the allocation concealment, which was ranked using the Cochrane approach:<BR/>Grade A: Adequate concealment<BR/>Grade B: Uncertain<BR/>Grade C: Clearly inadequate concealment<BR/>Grade D: Not used<BR/>Where there was uncertainty authors were contacted for clarification.</P>
<SUBSECTION>
<HEADING LEVEL="5">STATISTICAL CONSIDERATIONS</HEADING>
<P>The planned analysis was of analysis of doxapram vs placebo, doxapram vs non-invasive positive pressure ventilation (NIPPV) and doxapram vs other stimulants. Categorical outcomes were analysed as odds ratios. Continuous outcomes were analysed as weighted mean difference (WMD) with 95% confidence interval (CI). Where appropriate, data were entered as negative values to conform to the Cochrane convention whereby effects that favour the treatment under review move to the left.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-02 11:27:58 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION>
<P>Two of the four included papers compared doxapram with the same control. Only one paper (<LINK REF="STD-Moser-1973" TYPE="STUDY">Moser 1973</LINK>) compared doxapram with placebo. Two papers (<LINK REF="STD-Angus-1996" TYPE="STUDY">Angus 1996</LINK>; <LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK>) compared doxapram with NIPPV, while the fourth (<LINK REF="STD-Edwards-1967" TYPE="STUDY">Edwards 1967</LINK>) compared doxapram with four other respiratory stimulants: ethamivan, amiphenazole, prethcamide and nikethamide. </P>
<P>For a full description see the table of included studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-02 11:27:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The process of allocation was not adequanetly disclosed across the studies. Blinding was attempted in two of the studies where doxapram was compared with other respiratory stimulants or placebo. There was heterogeneity of patients with variable disease severity, and data were difficult to extract, with incomplete data presented in some cases. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-02 11:22:51 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The first electronic search identified twenty-five abstracts and papers from the database, of these only three were included for this review. Papers were excluded for the following reasons: review article (8); patients not spontaneously breathing (2); non-randomized trial (7); absence of ventilatory failure (4), other (1). A substantive update to this review was made in 2002 following the identification of an unpublished study (<LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK>). A subsequent update search conducted in October 2003 did not yield any further studies.</P>
<SUBSECTION>
<HEADING LEVEL="5">DOXAPRAM VERSUS OTHER RESPIRATORY STIMULANTS</HEADING>
<P>Two of the four studies were on small participant numbers, and in neither was a comparison made of doxapram versus placebo. The initial study (<LINK REF="STD-Edwards-1967" TYPE="STUDY">Edwards 1967</LINK>) made pre- and post-treatment comparisons between doxapram and four other respiratory stimulants, none of which are now in routine use. The infusions were given for four hours and measurements made at the end of the infusion and again 24 hours later. No oxygen was given during the 24 hours of the trial, which is contrary to currently accepted clinical practice. Statistical comparisons were made on data obtained after 24 hours and did not reflect the immediate changes in blood gases during the treatment period. This, however, probably underestimated the improvements in blood gas parameters that were directly attributable to the various respiratory stimulants, as other treatments (bronchodilators, antibiotics, diuretics) which were administered to all participants would have had time to effect some improvement. Nevertheless, only doxapram produced a significant increase in minute volume and had clear effects on increasing sputum expectoration. The toxicity of respiratory stimulants was not studied in great detail, but doxapram appeared the best tolerated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DOXAPRAM VERSUS PLACEBO</HEADING>
<P>The largest study was a multi-centre study of 78 participants (<LINK REF="STD-Moser-1973" TYPE="STUDY">Moser 1973</LINK>). Their underlying lung disease was not clearly documented and the age range (21 to 78 years) suggests that they may have been a heterogeneous group. All participants were given sufficient oxygen to raise PaO2 to between 60 and 70mmHg (8 to 9.3kPa) and either intravenous doxapram or placebo given for two hours. During this period arterial blood gases were measured and partcipants classified as a treatment failure if pH declined more than 0.06 or PaCO2 rose by 10 mm Hg (1.3 kPa), and also if intubation/tracheostomy was necessary. In the doxapram group 32 out of 40 participants maintained pH and PaCO2 within the preset limits, but only 22 out of 38 in the placebo group. The extent of the blood gas changes in the two groups is not clear, but there was a significant advantage in terms of pH (higher) and PaCO2 (lower) at all time points in the doxapram group. The authors commented that the long term outcome in terms of intubation or death did not correlate with the data obtained during the two hour infusion. Overall the mortality in this group of patients was high during the admission (19.2%). This study showed that during a short period of treatment doxapram allowed partial correction of hypoxia without deterioration in pH or PaCO2 more often than placebo. Morbidity associated with doxapram was barely considered in this study, although it is reported that one person developed a psychosis on doxapram.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DOXAPRAM VERSUS NIPPV</HEADING>
<P>
<LINK REF="STD-Angus-1996" TYPE="STUDY">Angus 1996</LINK> compared doxapram with a newly introduced treatment modality, NIPPV, in participants (n = 17) who had failed to respond to conventional treatment and who had ventilatory failure. Oxygen was given in variable concentrations to all participants and continued at the same rate throughout the study. Arterial blood gases were checked hourly for four hours. In the doxapram group mean PaO2 improved by 12.75 mm Hg (1.7 kPa) but this was not maintained, and PaCO2 failed to improve. In the NIPPV group mean PaO2 improved by 16.5 mm Hg (2.2 kPa), and mean PaCO2 fell by 10.5 mm Hg (1.4 kPa). Mean pH was higher in the NIPPV group. In the early part of the study three patients in the doxapram group of the study died and subsequently the protocol was modified; two patients deteriorating on doxapram received NIPPV and survived to discharge.</P>
<P>
<LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK> compared IV doxapram with non-invasive ventilation in a parallel group multi-centre high dependency setting. Twenty four participants were randomised to receive NIPPV and 25 received doxapram. All participants had acute exacerbations of COPD complicated by severe acute hypercapnic respiratory failure. 74% participants were recruited directly from acute medical assessment units. Due to uneven distribution of data parametric statistical tests were not possible. Blood gases were measured at 1, 4 and 24 hours. Particpants who were deemed treatment failures prior to 4 and 24 hours were excluded from the analysis. Two patients did not have measurements taken at 4 and 24 hours and so their values were not incorporated in to the analysis. No significant differences were observed with regard to hydrogen ion concentration levels or arterial carbon dioxide tensions. At one hour, median PaCO2 was 9.2 and 9.4 kPa, and PaO2 was 7.5 and 7.3 kPa in the NIPPV and doxapram groups respectively (N = 49). At four hours, patients treated with NIPPV had a median PaCO2 of 8.6 kPa compared with 8.3 in the doxapram group. Median PaO2 was significantly higher in the group treated with NIPPV compared with those treated with doxapram at 4 hours (8.0 versus 6.8 kPa, p = 0.04) (n = 39, NIPPV: n = 19, Dox: n = 20). No significant differences were observed at 24 hours (p = 0.08, n = 13, NIPPV: n = 8, Dox: n = 5). Hydrogen ion concentration levels improved in both groups one hour after baseline. Length of stay remained very similar in both groups with patients remaining in hospital for a median of 12 and 10 days in the NIPPV and doxapram groups respectively (p = 1.0). Intubation and mechanical ventilation rates were low in this study (2/25 in the doxapram group and 1/24 in the NIPPV group). Treatment failure was defined as failure to maintain PaO2 above 6 kPa and/or H+ nmols/l below 50 after four hours of treatment. According to these criteria, there were 34 treatment failures by 24 hours. The distribution of the treatment failures was even between the two groups. Please see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for distribution and cause of treatment failures at different time-points. There was high mortality in both groups (11/24 in the NIPPV group and 10/25 in the doxapram group after 24 hours). Within 24 hours there was one death reported, but it was not evident in which treatment group the death occured. Median survival was four days. A post hoc subgroup analysis by treatment failure did not detect any differences.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Respiratory stimulants are still commonly prescribed for the management of patients with ventilatory failure secondary to exacerbations of chronic obstructive pulmonary disease (COPD). This systematic review demonstrates the paucity of clinical data concerning the efficacy of these drugs in COPD.</P>
<P>Initially there were at least five different respiratory stimulants available and doxapram was shown in a single small trial to be the most effective at improving gas abnormalities, and to be the best tolerated (<LINK REF="STD-Edwards-1967" TYPE="STUDY">Edwards 1967</LINK>). Secondary benefits included increased sputum volume. Overall the design of the study made treatment comparisons difficult: small participant numbers (n = 32) were randomly allocated to one of five respiratory stimulants and data was presented of the effects before and after treatment. Thus comparisons between treatment groups are not matched as each patient only received one treatment. Nevertheless the statistical analysis in the published study compared differences in treatment effect for each of the five treatments.</P>
<P>A larger study (<LINK REF="STD-Moser-1973" TYPE="STUDY">Moser 1973</LINK>) looked at the short-term benefits of doxapram administration and classified outcomes dichotomously in terms of success or failure, by a pre-determined amount. Secondary end points included progression to artificial ventilation. This study suggested that the administration of doxapram had some benefit slowing deterioration in participants acutely ill with hypercapnia, but the extent of the physiological improvement could not be easily determined.</P>
<P>A more recent study (<LINK REF="STD-Angus-1996" TYPE="STUDY">Angus 1996</LINK>) with few participants (n = 17) compared doxapram infusion with non-invasive ventilation using a tight-fitting nasal mask (NIPPV). This showed the latter treatment to be superior both in terms of blood gas improvement at four hours and survival at 24 hours. All participants receiving NIPPV survived to discharge. In this study the authors did not adjust the dose to achieve maximum clinical benefit but used a standard dosage regimen. The <LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK> study recruited COPD participants with acute ventilatory failure. Participants had severe disease as judged by a per cent predicted FEV1 of 28% and 35% had had a prior episode of acute ventilatory failure. Allowing for the high attrition rate (of the 49 participants enrolled, 13 contributed data to the final reading at 24 hours), there was no difference between NIPPV and doxapram in terms of blood gas and acidosis. Furthermore of the 34 participants deemed to have failed at 24 hours there seemed to be no difference between doxapram and NIPPV failure rate. The discrepancy between the <LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK> and the <LINK REF="STD-Angus-1996" TYPE="STUDY">Angus 1996</LINK> studies might be partly explained by differences in participants populations. Although the <LINK REF="STD-Angus-1996" TYPE="STUDY">Angus 1996</LINK> study did not present data on previous episodes of ventilatory failure, it can be assumed that the <LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK> study participants were much more severe and likely to have end stage COPD. This is based on the fact that there was a very high inpatient mortality (42%), and that only three participants were selected for intubation and mechanical ventilation. It is likely that those considered unsuitable for intensive care were highly disabled (e.g. housebound ) with significant co-morbidity such that intensive resuscitation was not considered appropriate. Furthermore, the pre-treatment pH of 7.26 (55 H+ nmols/L) compares unfavourably with the admission pH of 7.3 in <LINK REF="STD-Angus-1996" TYPE="STUDY">Angus 1996</LINK>, for it is well recognised that pH is a sensitive predictor of outcome in patients with acute COPD (<LINK REF="STD-Jeffrey-1992" TYPE="STUDY">Jeffrey 1992</LINK>).</P>
<P>Although the <LINK REF="STD-Newman-2001" TYPE="STUDY">Newman 2001</LINK> study indicates that NIPPV is not a panacea for hypercapnic respiratory failure, it should be noted that the technique of ventilation, although adequate in terms of duration (mean ventilation 14 hours on day one), was probably suboptimal in terms of levels of inspiratory pressure (mean 11.2 cm), as most successful trials of NIPPV have used considerably higher inspiratory pressures (<LINK REF="REF-Plant-2000" TYPE="REFERENCE">Plant 2000</LINK>; <LINK REF="REF-BTS-2002" TYPE="REFERENCE">BTS 2002</LINK>). </P>
<P>Two of these three studies show doxapram has short term benefits in improving arterial blood gases in participants with COPD and hypercapnic respiratory failure. There was no obvious improvement in survival in hospital in the doxapram treated group and one recent study suggests that doxapram is inferior to non-invasive ventilation. Although non-invasive ventilation is considered the preferred mode of treatment in many hospitals, it cannot be delivered in all emergency settings and it is likely that there will still be a role for doxapram while other drug treatments are given time to act or when patients cannot tolerate NIPPV. Whilst acknowledging the dearth of evidence that doxapram reduces intubation rate or mortality, many clinicians would feel uncomfortable entering patients into a placebo controlled trial, given the high mortality rate associated with ventilatory failure. Further trials of doxapram versus NIPPV are important and could be extended to examine the effects of either of these treatments versus a combination of the two. Ideally studies will include adequate numbers, an economic evaluation to include staffing and equipment costs, and efficacy outcomes beyond changes in blood gas parameters.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Little is known about the current prescribing of doxapram in hospitals but its use is advocated in both undergraduate and specialist texts and numerous review articles. </P>
<P>Doxapram appears to have become an established treatment for ventilatory failure secondary to exacerbations of COPD on very limited trial data and largely based on extrapolation from the anaesthetic literature where its role in reversing CO2 narcosis is established. However, the rationale for its use in COPD is less convincing and largely unsupported by published data with satisfactory trial design, clinically important outcomes, or adequate numbers. Many respiratory units have now established non-invasive ventilation for ventilatory failure secondary to COPD, and doxapram use is likely to diminish. </P>
<P>It may still have a role as a short-term measure to facilitate oxygen therapy while other pharmacological treatments are given time to work or while the patient is transferred to a setting where ventilation (invasive or non-invasive) can be established. It should also be considered for those patients who cannot tolerate NIPPV. Titration of the dose to achieve maximum clinical benefit may be more appropriate than the use of fixed dose regimes. </P>
<P>The most recent data comparing NIPPV with doxapram confirm the grave prognosis of acidotic ventilatory failure, and suggests that in the most severely affected patients neither treatment is particularly effective at reversing blood abnormalities, and that the prognosis is poor regardless of treatment. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Despite the establishment of doxapram in most hospital formularies, the limited data available from the trials reviewed here suggests a need for more critical studies to evaluate the efficacy of this drug. None of the reviewed studies have examined the morbidity associated with its use (which clinical experience suggests is considerable), nor the optimum duration of treatment when initial improvement is inadequate. End points such as duration and severity of abnormal blood gas concentrations, progression to ventilation and length of hospital stay would all be important clinical markers of efficacy, and have clear financial implications. Although there are gaps in our understanding of the place of doxapram as add-in therapy, the main focus of future research is likely to be in comparison with non-invasive ventilatory support in the treatment of hypercapnic exacerbations. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to thank the staff of the Cochrane Airways Group editorial base for sustained support with the review. Clerical, administrative and technical support with electronic searching and retrieving papers were gratefully received from Karen Blackhall and Bettina Reuben. Kirsty Olsen copy edited this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>MG initially developed the protocol and review. TL read through abstracts and assessed quality for the updaed version of the review. TL and MG entered data and developed the analysis and discussion in the updated version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Angus-1996" NAME="Angus 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Contains cohort of Angus 1996&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed AH, Fenwick L, Angus RM, Peacock</AU>
<TI>Nasal ventilation versus doxapram in the treatment of type II respiratory failure complicating chronic airflow obstruction</TI>
<SO>Thorax</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>858</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angus RM, Ahmed AEA, Fenwick LJ, Peacock AJ</AU>
<TI>Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>10</NO>
<PG>1048-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1967" NAME="Edwards 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Lancet 1967 (July):226-9&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards G, Leszczynski SO</AU>
<TI>A double-blind trial of five respiratory stimulants in patients in acute ventilatory failure</TI>
<SO>Lancet</SO>
<YR>1967</YR>
<PG>226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moser-1973" NAME="Moser 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moser KM, Luchsinger PC, Adamson JS, McMahon SM, Schlueter DP, Spivack M, Weg JG</AU>
<TI>Respiratory stimulation with intravenous doxapram in respiratory failure. A double-blind co-operative study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1973</YR>
<VL>288</VL>
<NO>9</NO>
<PG>427-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Newman-2001" NAME="Newman 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr J, Douglas NJ, Banham SJ, Innes A, Bell D, Mackay T et al</AU>
<TI>Randomised trial of NIPPV versus doxapram in acute on chronic respiratory failure ni patients with exacerbations of COPD</TI>
<SO>American Journal or Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>3</NO>
<PG>A579</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Newman WJ, Banham SJ, Barr J, Bell D, Douglas NJ, Innes AJ et al</AU>
<TO>A randomised trial comparing non-invasive ventilation with the respiratory stimulant, doxapram, in the treatment of acute hypercapnic respiratory failure complicating exacerbations of chronic obstructive pulmonary disease</TO>
<SO>Author copy</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1989" NAME="Andersen 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen JB, Jensen NH, Klausen NO</AU>
<TI>A pharmacologic respiratory stimulant, (doxapram), used in acute deterioration in patients with chronic respiratory failure</TI>
<SO>Ugeskr-Laeger</SO>
<YR>1989</YR>
<VL>151</VL>
<NO>28</NO>
<PG>1820-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1973" NAME="Anonymous 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Anonymous,  A new stimulant for ventilatory failure?. Lancet 1973 Apr 7; 1 806: 753-5&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>A new stimulant for ventilatory failure?</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>1806</VL>
<PG>753-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aubier-1980" NAME="Aubier 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aubier M, Murciano D, Milic-Emili J et al</AU>
<TI>Effects of the administration of oxygen on ventilation and blood gases in patients with chronic obstructive pulmonry disease during acute respiratory failure</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1980</YR>
<VL>122</VL>
<PG>747-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bone-1980" NAME="Bone 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC</AU>
<TI>Treatment of respiratory failure due to advanced chronic obstructive lung disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1980</YR>
<VL>140</VL>
<NO>8</NO>
<PG>1018-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnaud-1982" NAME="Bonnaud 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnaud F, Malauzat C, Eichler B, Germouty J</AU>
<TI>Major lines of treatment in chronic bronchitis</TI>
<TO>Les grands axes du traitement de la bronchite chronique</TO>
<SO>Gazette Medicale de France</SO>
<YR>1982</YR>
<VL>89</VL>
<NO>17</NO>
<PG>1957-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bott-1993" NAME="Bott 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Bott J.,  Carroll M. P.,  Conway J. H.,  Keilty S. E.,  Ward E. M.,  Brown A. M., Paul E. A.,  Elliott M. W.,  Godfrey R. C.,  Wedzicha J. A.  et al.  Randomized Controlled Trial. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease [see comments]. Lancet 1993 Jun 19; 341 8860: 1555-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bott J, Carroll MP, Conway JH, Keilty SE, Ward EM, Brown AM et al</AU>
<TI>Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8860</NO>
<PG>1555-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burki-1984" NAME="Burki 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Burki N.K. Ventilatory effects of doxapram in conscious human subjects. Chest 1984; 85: 600-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burki NK</AU>
<TI>Ventilatory effects of doxapram in conscious human subjects</TI>
<SO>Chest</SO>
<YR>1984</YR>
<VL>85</VL>
<PG>600-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canter-1964" NAME="Canter 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canter HG, Luchsinger PC</AU>
<TI>The treatment of respiratory failure without mechanical assistance</TI>
<SO>The American Journal of the Medical Sciences</SO>
<YR>1964</YR>
<VL>248</VL>
<PG>206-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chin-1983" NAME="Chin 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Chin R, Pesce R. Practical aspects in management of respiratory failure in chronic obstructive pulmonary disease. Critical Care Quarterly 1983; 6(2): 1-21&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chin R, Pesce R</AU>
<TI>Practical aspects in management of respiratory failure in chronic obstructive pulmonary disease</TI>
<SO>Critical Care Quarterly</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>2</NO>
<PG>1-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conti-1976" NAME="Conti 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Conti F.  Bertoli L.  Bertoli M.  Mantero O.  Ventilatory and pulmonary hemodynamic response to the respiratory stimulant doxapram in chronic bronchitis. Pharmacological Research Communications 1976; 8(3): 243-51&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conti F, Bertoli L, Bertoli M, Mantero O</AU>
<TI>Ventilatory and pulmonary hemodynamic response to the respiratory stimulant doxapram in chronic bronchitis</TI>
<SO>Pharmacological Research Communications</SO>
<YR>1976</YR>
<VL>8</VL>
<NO>3</NO>
<PG>243-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derenne-1988" NAME="Derenne 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Derenne J-P, Fleurey B, Pariente R. State of the Art: Acute respiratory failure of chronic obstructive pulmonary disease. Am Rev Respir Dis 1988 138: 1006-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derenne JP, Fleurey B, Pariente R</AU>
<TI>State of the Art: Acute respiratory failure of chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1988</YR>
<VL>138</VL>
<PG>1006-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hennes-1966" NAME="Hennes 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Hennes HH, Osterkamp E. Doxapram hydrochloride (dopram) and its influence on the ventilation values in unanesthetized subjects Der Anaesthesist 15(7): 241-43&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hennes HH, Osterkamp E</AU>
<TI>Doxapram hydrochloride (dopram) and its influence on the ventilation values in unanesthetized subjects</TI>
<SO>Der Anaesthesist</SO>
<YR>1966</YR>
<VL>15</VL>
<NO>7</NO>
<PG>241-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1990" NAME="Jansen 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Jansen J.E., Sorensen A.I., Naesh O., Erichsen C.J., Pedersen A. Effect of doxapram on postoperative pulmonary complications after upper abdominal surgery in high-risk patients. Lancet 1990 335: 936-938.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jansen JE, Sorensen AI, Naesh O, Erichsen CJ, Pedersen A</AU>
<TI>Effect of doxapram on postoperative pulmonary complications after upper abdominal surgery in high-risk patients</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>936-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeffrey-1992" NAME="Jeffrey 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeffrey AA, Warren PM, Flenley DC</AU>
<TI>Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management</TI>
<SO>Thorax</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Light-1983" NAME="Light 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Light RW. Conservative treatment of hypercapnic acute respiratory failure. Respiratory Care 1983; 28(5): 561-566&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Light RW</AU>
<TI>Conservative treatment of hypercapnic acute respiratory failure</TI>
<SO>Respiratory Care</SO>
<YR>1983</YR>
<VL>28</VL>
<NO>5</NO>
<PG>561-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohi-1978" NAME="Ohi 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Ohi M, Nakashima M, Heki S, Kato M, Sagawa Y. Doxapram hydrochloride in the treatment of acute exacerbation of chronic respiratory failure. Chest 1978; 74: 453-4&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohi M, Nakashima M, Heki S, Kato M, Sagawa Y</AU>
<TI>Doxapram hydrochloride in the treatment of acute exacerbation of chronic respiratory failure</TI>
<SO>Chest</SO>
<YR>1978</YR>
<VL>74</VL>
<PG>453-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pourriat-1992" NAME="Pourriat 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Pourriat J. L.,  Baud M.,  Lamberto C.,  Fosse J. P.,  Cupa, M.  Effects of doxapram on hypercapnic response during weaning from mechanical ventilation in COPD patients. Chest 1992; 101(6): 1639-43&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pourriat JL, Baud M, Lamberto C, Fosse JP, Cupa M</AU>
<TI>Effects of doxapram on hypercapnic response during weaning from mechanical ventilation in COPD patients</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<NO>6</NO>
<PG>1639-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prendergast-1974" NAME="Prendergast 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Prendergast M.P. The use of respiratory stimulants in respiratory failure. The British Journal of Clinical Practice 1974; 28(1):&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prendergast MP</AU>
<TI>The use of respiratory stimulants in respiratory failure</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1974</YR>
<VL>28</VL>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riordan-1974" NAME="Riordan 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riordan JF, Sillett RW, McNichol MW</AU>
<TI>Response to a respiratory stimulant (doxapram) in severe respiratory failure</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1974</YR>
<VL>68</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riordan-1975" NAME="Riordan 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Riordan J.F., Sillett, R.W., McNichol, M.W. A controlled trial of doxapram in acute respiratory failure.&lt;br&gt;Brit J Dis Chest 1975; 69: 57-62&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riordan JF, Sillett RW, McNichol MW</AU>
<TI>A controlled trial of doxapram in acute respiratory failure</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1975</YR>
<VL>69</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1974" NAME="Simpson 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Simpson R., Singh N.P., Jagannadham A. Respiratory Stimulants. Fourth Asian and Australasian Congress of Anaesthesiologists 1974; 187-191&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson R, Singh NP, Jagannadham A</AU>
<TI>Respiratory Stimulants</TI>
<SO>Fourth Asian and Australasian Congress of Anaesthesiologists</SO>
<YR>1974</YR>
<VL>187-91</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warren-1980" NAME="Warren 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Warren P.M., Flenley D.C., Miller J.S., Avery A. Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76. Lancet 1980; i: 467-71.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren PM, Flenley DC, Miller JS, Avery A</AU>
<TI>Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>467-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-BTS-2002" MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 2002" TYPE="JOURNAL_ARTICLE">
<AU>BTS Standards of care committee</AU>
<TO>Non-invasive ventilation in acute respiratory failure</TO>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>192-211</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plant-2000" MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Plant 2000" TYPE="JOURNAL_ARTICLE">
<AU>Plant PK, Owen JL, Elliott MW</AU>
<TO>Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial</TO>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>1931-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-02 11:23:53 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-09-02 11:23:53 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Angus-1996">
<CHAR_METHODS>
<P>Randomised, not blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 patients with acute exacerbations of COPD and ventilatory failure (PaO2 less than 8kPa and PaCO2 greater than 6.7kPa)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous doxapram infusion for 4 hours (4mg per minute for 15 mins, 3mg per minute for 30 mins, 2mg per <BR/>minute for 60 mins, 1.5mg per minute as maintenance).<BR/>Nasal intermittent positive pressure ventilation using a pressure cycled machine set between 14 to 18cm water.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hourly arterial blood gases, mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-02 11:23:42 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Edwards-1967">
<CHAR_METHODS MODIFIED="2008-09-02 11:23:42 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Random allocation; double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>32 COPD patients in 'acute ventilatory failure'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>One of five respiratory stimulants: doxapram (3mg per kg per hr); ethamivan (12 mg per kg per hr); amiphenazole (3mg per kg per hr); prethcamide (12mg per kg per hr); nikethamide (15mg per kg per hr) infusions for four hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PCO2, oxygen saturation, tidal volume, minute-volume, FEV1 at 4 hours.<BR/>Sputum volume, clinical response, proportional reduction of initial hypoxic and hypercapnic gap at 24 hours.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ventilatory failure not defined, but all group mean PCO2 greater than 50mm Hg.<BR/>Small numbers in each group (n = 6 or 7).h</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-02 11:23:53 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Moser-1973">
<CHAR_METHODS MODIFIED="2008-09-02 11:23:53 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Randomised. Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>78 patients with COPD and acute respiratory failure (PaCO2 greater than 50mm Hg, PaO2 less than 50mm Hg).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Doxapram (2.8mg per min) or placebo infusion for 2 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Arbitrary improvement or failure (rise in PaCO2 of 10mm Hg or more, or pH decline, or intubation or tracheostomy).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Newman-2001">
<CHAR_METHODS>
<P>Randomised, unblinded parallel group study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>49 patients with a mean age of 66.5 +/- 8.39 and a diagnosis of acute COPD made by a consultant respiratory chest physician (PaCO2 greater than or equal to 6.6kPa, H+greater than or equal to 50 nmols/l)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Doxapram was administered via continuous intravenous <BR/>infusion (45mgs per hour initially. This dosage was titrated).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Arterial blood gas parameters measured at 1, 4 and 24 hours. Length of hospital stay, treatment failures, mortality and intubation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Andersen-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>11 out of 25 patients received mechanical ventilation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aubier-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>No doxapram given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bone-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonnaud-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bott-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only 43% of conventional treatment group received doxapram.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burki-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Normal subjects not in ventilatory failure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Canter-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chin-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Conti-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients not in ventilatory failure, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Derenne-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hennes-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Healthy subjects not in ventilatory failure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jansen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients not in ventilatory failure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jeffrey-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Light-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohi-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pourriat-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients on ventilators through long term tracheostomies i.e. not spontaneously breathing.<BR/>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prendergast-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riordan-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riordan-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article, not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Warren-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT, only 29% of subjects received a respiratory stimulant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-02 11:24:03 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-02 11:24:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-02 11:23:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Angus-1996">
<DESCRIPTION>
<P>Insufficient information available to ascertain degree of bias in allocation procedure (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-02 11:23:51 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1967">
<DESCRIPTION>
<P>Insufficient information available to ascertain degree of bias in allocation procedure (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-02 11:23:58 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Moser-1973">
<DESCRIPTION>
<P>Insufficient information available to ascertain degree of bias in allocation procedure (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-02 11:24:03 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Newman-2001">
<DESCRIPTION>
<P>Insufficient information available to ascertain degree of bias in allocation procedure (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-09-02 11:15:29 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Rate of treatment failures in doxapram and NIPPV groups (Newman 2001)</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Doxapram</P>
</TH>
<TH>
<P>NIPPV</P>
</TH>
</TR>
<TR>
<TD>
<P>Number of failures@ &lt; 4 hours</P>
</TD>
<TD>
<P>4 (4 on clinical grounds)</P>
</TD>
<TD>
<P>4 (1 on clinical grounds; 3 unable to tolerate NIV)</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of failures @ 4 hours</P>
</TD>
<TD>
<P>12 (10 with H+ &gt;50; 2 with PaO2 &lt;6)</P>
</TD>
<TD>
<P>10 (10 with H+ &gt;50)</P>
</TD>
</TR>
<TR>
<TD>
<P>Number of failures @ &gt; 4 hours</P>
</TD>
<TD>
<P>3 (3 on clinical grounds)</P>
</TD>
<TD>
<P>1 (1 on clinical grounds)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Doxapram vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Frequency of unsatisfactory response</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0243255127747122" CI_START="0.14015145921889252" EFFECT_SIZE="0.37889406874549547" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.010437989781668468" LOG_CI_START="-0.8534023761240748" LOG_EFFECT_SIZE="-0.42148219317120317" ORDER="336" O_E="-3.76923076923077" SE="0.5074241070118085" STUDY_ID="STD-Moser-1973" TOTAL_1="40" TOTAL_2="38" VAR="3.883808499193114" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Intubation/ventilation</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2723591104834417" CI_START="0.5122209021872286" EFFECT_SIZE="1.294670126268628" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.5148609573292022" LOG_CI_START="-0.29054270326049475" LOG_EFFECT_SIZE="0.11215912703435366" ORDER="337" O_E="1.1538461538461533" SE="0.47309809704280636" STUDY_ID="STD-Moser-1973" TOTAL_1="40" TOTAL_2="38" VAR="4.467839852455237" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Doxapram vs. nikethamide</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PaCO2 (mm Hg) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Nikethamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Nikethamide better</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.965402593062402" CI_START="-20.434597406937606" EFFECT_SIZE="-10.700000000000003" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="55.7" ORDER="338" SD_1="7.6" SD_2="9.5" SE="4.9667225947634055" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen saturation - after treatment</NAME>
<GROUP_LABEL_1>Nikethamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Doxapram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Nikethamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.57732686981449" CI_START="0.42267313018551" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="86.5" MEAN_2="79.5" ORDER="339" SD_1="4.9" SD_2="6.6" SE="3.355840679571464" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Tidal volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Nikethamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Doxapram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Nikethamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.19156776574868634" CI_START="0.04843223425131375" EFFECT_SIZE="0.12000000000000005" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="0.43" ORDER="340" SD_1="0.04" SD_2="0.08" SE="0.03651483716701108" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Minute volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Nikethamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Nikethamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.895367118264345" CI_START="-0.43536711826434793" EFFECT_SIZE="2.7299999999999986" ESTIMABLE="YES" MEAN_1="13.45" MEAN_2="10.72" ORDER="341" SD_1="3.6" SD_2="1.64" SE="1.615012899845282" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Sputum volume (mls) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Nikethamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Nikethamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="39.05725250894641" CI_START="12.54274749105358" EFFECT_SIZE="25.799999999999997" ESTIMABLE="YES" MEAN_1="65.8" MEAN_2="40.0" ORDER="342" SD_1="10.7" SD_2="12.65" SE="6.764028631912592" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Nikethamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Nikethamide better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7575825797758686" CI_START="0.009939225711707519" EFFECT_SIZE="0.08677432947392923" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.12057002026956071" LOG_CI_START="-2.002647446813004" LOG_EFFECT_SIZE="-1.0616087335412825" ORDER="343" O_E="-2.0" SE="1.1055415967851334" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" VAR="0.8181818181818181" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Doxapram vs. prethcamide</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PaCO2 (mm Hg) - after treatment</NAME>
<GROUP_LABEL_1>Doaxpram</GROUP_LABEL_1>
<GROUP_LABEL_2>Prethcamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Prethcamide better</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.898572790842551" CI_START="-11.498572790842545" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="49.3" ORDER="344" SD_1="7.6" SD_2="5.2" SE="3.67280870853953" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen saturation - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Prethcamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prethcamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.48283629081275" CI_START="3.5171637091872494" EFFECT_SIZE="10.5" ESTIMABLE="YES" MEAN_1="86.5" MEAN_2="76.0" ORDER="345" SD_1="4.9" SD_2="7.8" SE="3.562737043074501" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Tidal volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Prethcamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prethcamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.16735413825912449" CI_START="0.03264586174087557" EFFECT_SIZE="0.10000000000000003" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="0.45" ORDER="346" SD_1="0.04" SD_2="0.08" SE="0.03436498771936898" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Minute volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Better</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prethcamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.562141851972042" CI_START="0.39785814802795505" EFFECT_SIZE="3.4799999999999986" ESTIMABLE="YES" MEAN_1="13.45" MEAN_2="9.97" ORDER="347" SD_1="3.6" SD_2="1.48" SE="1.5725502490268113" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Sputum volume (mls) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Prethcamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prethcamide better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="40.47327757565382" CI_START="18.46672242434618" EFFECT_SIZE="29.47" ESTIMABLE="YES" MEAN_1="65.8" MEAN_2="36.33" ORDER="348" SD_1="10.7" SD_2="9.33" SE="5.614020289375859" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Prethcamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Prethcamide better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0698332100249452" CI_START="0.01599418646467195" EFFECT_SIZE="0.13080944861605956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.029316075244093766" LOG_CI_START="-1.7960378451634447" LOG_EFFECT_SIZE="-0.8833608849596754" ORDER="349" O_E="-1.7692307692307692" SE="1.0722219284950192" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" VAR="0.8698224852071007" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Doxapram vs. amiphenazole</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PaCO2 (mm Hg) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Amiphenazole better</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2610151240635403" CI_START="-17.461015124063543" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="53.6" ORDER="350" SD_1="7.6" SD_2="8.7" SE="4.5210091583101" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen saturation - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.71714346217576" CI_START="0.18285653782424482" EFFECT_SIZE="6.450000000000003" ESTIMABLE="YES" MEAN_1="86.55" MEAN_2="80.1" ORDER="351" SD_1="4.9" SD_2="6.6" SE="3.1975809308794374" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Tidal volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.01735413825912442" CI_START="-0.11735413825912451" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="-0.55" MEAN_2="-0.5" ORDER="352" SD_1="0.04" SD_2="0.08" SE="0.03436498771936898" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Minute volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.276267628910918" CI_START="0.02373237108907933" EFFECT_SIZE="3.1499999999999986" ESTIMABLE="YES" MEAN_1="13.45" MEAN_2="10.3" ORDER="353" SD_1="3.6" SD_2="1.64" SE="1.5950638142182811" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Sputum volume (mls) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="37.96529451607627" CI_START="-36.365294516076275" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="65.8" MEAN_2="65.0" ORDER="354" SD_1="10.7" SD_2="48.82" SE="18.962233392670157" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Amiphenazole better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7768498375825064" CI_START="0.02394525970343919" EFFECT_SIZE="0.20626955862396867" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.24965072692466447" LOG_CI_START="-1.6207804483620736" LOG_EFFECT_SIZE="-0.6855648607187046" ORDER="355" O_E="-1.3076923076923075" SE="1.0987005311470714" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="7" VAR="0.8284023668639053" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Doxapram vs. ethamivan</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PaCO2 (mm Hg) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Amiphenazole better</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.8436596388524364" CI_START="-10.243659638852442" EFFECT_SIZE="-1.7000000000000028" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="46.7" ORDER="356" SD_1="7.6" SD_2="7.5" SE="4.359090119126543" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen saturation - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.363256500645335" CI_START="-2.663256500645347" EFFECT_SIZE="3.8499999999999943" ESTIMABLE="YES" MEAN_1="86.55" MEAN_2="82.7" ORDER="357" SD_1="4.9" SD_2="6.5" SE="3.323151115031234" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Tidal volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.10451031226932102" CI_START="-0.024510312269320947" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="0.51" ORDER="358" SD_1="0.04" SD_2="0.07" SE="0.03291402943021917" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Minute volume (litres) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.861986643614568" CI_START="0.9380133563854289" EFFECT_SIZE="4.399999999999999" ESTIMABLE="YES" MEAN_1="13.45" MEAN_2="9.05" ORDER="359" SD_1="3.6" SD_2="2.4" SE="1.7663521732655694" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Sputum volume (mls) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Amiphenazole better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.31361281344688" CI_START="-18.05361281344689" EFFECT_SIZE="-0.8700000000000045" ESTIMABLE="YES" MEAN_1="65.8" MEAN_2="66.67" ORDER="360" SD_1="10.7" SD_2="18.62" SE="8.767310496003512" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Failure to improve</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>Amiphenazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Amiphenazole better</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.404410523896844" CI_START="0.03626707357057318" EFFECT_SIZE="0.4427213051974648" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7327483310034808" LOG_CI_START="-1.4404874866976691" LOG_EFFECT_SIZE="-0.35386957784709416" ORDER="361" O_E="-0.5" SE="1.276569477008451" STUDY_ID="STD-Edwards-1967" TOTAL_1="6" TOTAL_2="6" VAR="0.6136363636363635" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Doxapram vs. NIPPV</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Best achieved PaO2 (kPa) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>NIPPV</GROUP_LABEL_2>
<GRAPH_LABEL_1>NIPPV better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Doxapram better</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7289132449644207" CI_START="-2.3289132449644203" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="8.1" ORDER="362" SD_1="1.41" SD_2="1.8" SE="0.7800721120511872" STUDY_ID="STD-Angus-1996" TOTAL_1="8" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Best achieved PaCO2 (kPa) - after treatment</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>NIPPV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>NIPPV better</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.358444423393743" CI_START="-0.5584444233937425" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="8.7" ORDER="363" SD_1="2.26" SD_2="1.8" SE="0.9992246994545321" STUDY_ID="STD-Angus-1996" TOTAL_1="8" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Mortality at 24 hours</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>NIPPV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>NIPPV better</GRAPH_LABEL_2>
<DICH_DATA CI_END="128.0217614194686" CI_START="1.004954831363273" EFFECT_SIZE="11.34266669078005" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1072837982502803" LOG_CI_START="0.002146542422657155" LOG_EFFECT_SIZE="1.0547151703364688" ORDER="364" O_E="1.588235294117647" SE="1.2365680446706235" STUDY_ID="STD-Angus-1996" TOTAL_1="8" TOTAL_2="9" VAR="0.6539792387543252" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="5" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Addition of the alternative treatment modality</NAME>
<GROUP_LABEL_1>Doxapram</GROUP_LABEL_1>
<GROUP_LABEL_2>NIPPV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Doxapram better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>NIPPV better</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.11081179076506" CI_START="0.3775391398846135" EFFECT_SIZE="4.919790721239043" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.806931276088499" LOG_CI_START="-0.4230380179294501" LOG_EFFECT_SIZE="0.6919466290795245" ORDER="365" O_E="0.9285714285714286" SE="1.3098950018321758" STUDY_ID="STD-Angus-1996" TOTAL_1="5" TOTAL_2="9" VAR="0.5828100470957613" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>